GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » Net-Net Working Capital

Tesaro (Tesaro) Net-Net Working Capital : $-5.21 (As of Sep. 2018)


View and export this data going back to 2012. Start your Free Trial

What is Tesaro Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Tesaro's Net-Net Working Capital for the quarter that ended in Sep. 2018 was $-5.21.

The industry rank for Tesaro's Net-Net Working Capital or its related term are showing as below:

TSRO's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.05
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Tesaro Net-Net Working Capital Historical Data

The historical data trend for Tesaro's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro Net-Net Working Capital Chart

Tesaro Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Net-Net Working Capital
Get a 7-Day Free Trial 3.60 3.24 1.56 10.60 1.82

Tesaro Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.31 1.82 -0.78 -3.40 -5.21

Competitive Comparison of Tesaro's Net-Net Working Capital

For the Biotechnology subindustry, Tesaro's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tesaro's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tesaro's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Tesaro's Price-to-Net-Net-Working-Capital falls into.



Tesaro Net-Net Working Capital Calculation

Tesaro's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2017 is calculated as

Net-Net Working Capital(A: Dec. 2017 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(643.095+0.75 * 53.416+0.5 * 57.939-613.099
-0-0)/54.464
=1.82

Tesaro's Net-Net Working Capital (NNWC) per share for the quarter that ended in Sep. 2018 is calculated as

Net-Net Working Capital(Q: Sep. 2018 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(476.812+0.75 * 31.362+0.5 * 108.822-841.632
-0-0)/55.035
=-5.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Tesaro  (NAS:TSRO) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Tesaro Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Tesaro's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Tesaro (Tesaro) Business Description

Traded in Other Exchanges
N/A
Address
Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.
Executives
Mary Lynne Hedley director, officer: President & COO C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr. officer: SVP & Chief Medical Officer C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr director, officer: Chief Executive Officer C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson officer: Exec. VP, CFO C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle officer: Sr. VP, Chief Commercial Ofc C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg director
Joseph L Farmer officer: Sr VP, Gen Counsel & Secretary C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins 10 percent owner

Tesaro (Tesaro) Headlines

From GuruFocus